Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295881566> ?p ?o ?g. }
Showing items 1 to 61 of
61
with 100 items per page.
- W4295881566 endingPage "B181" @default.
- W4295881566 startingPage "B180" @default.
- W4295881566 abstract "Midostaurin is a novel, orally available Fms-like tyrosine kinase 3 (FLT3) tyrosine kinase inhibitor that induces cell cycle arrest and apoptosis of leukemic cells expressing mutant and wild type FLT3 receptors, and has shown potential synergism with cytotoxic chemotherapy.We conducted a phase I study of azacitidine (intravenous 75 mg/m2 daily for 7 days) with escalating doses of oral midostaurin (25 mg twice per day [b.i.d.], 50 mg b.i.d., and 75 mg b.i.d.) on days 8 to 21 of a 28-day cycle in untreated acute myeloid leukemia (AML) in older patients and/or relapsed AML. Patients were eligible regardless of FLT3 mutation status. Trough blood samples for pharmacokinetics were obtained on days 8, 15, and 21 before midostaurin dosing.Seventeen patients with a median age of 73 (range, 57-83) years were enrolled; 5 patients had previous conventional treatment and none of the patients had FLT3 mutations. Dose-limiting toxicities were not observed. Hospitalizations, primarily for infections, occurred in one-third of treatment cycles. Fourteen patients were evaluable for response: 3 attained complete remission and 2 had hematologic improvement. Median (range) survival from enrollment was 6 (1 to ≥ 19) months. Three patients died within 60 days of enrollment (2 progressive disease, 1 non–dose-limiting toxicity, treatment-related). Pharmacokinetic data at 75 mg orally b.i.d. showed increased trough levels of midostaurin during cycle 2 compared with cycle 1 and persistent and increasing levels of its active metabolite, CGP52421.The combination of sequential azacitidine and midostaurin is safe and tolerable with response rates comparable with azacitidine alone and should be studied further in FLT3 mutation-positive AML." @default.
- W4295881566 created "2022-09-15" @default.
- W4295881566 creator A5015613174 @default.
- W4295881566 creator A5039695487 @default.
- W4295881566 creator A5053931061 @default.
- W4295881566 creator A5064763469 @default.
- W4295881566 date "2022-09-01" @default.
- W4295881566 modified "2023-10-09" @default.
- W4295881566 title "TCT-448 In-Hospital Outcomes of Transcatheter Aortic Valve Replacement in Systolic Heart Failure: An Analysis From the National In-Patient Sample 2012-2019" @default.
- W4295881566 doi "https://doi.org/10.1016/j.jacc.2022.08.527" @default.
- W4295881566 hasPublicationYear "2022" @default.
- W4295881566 type Work @default.
- W4295881566 citedByCount "0" @default.
- W4295881566 crossrefType "journal-article" @default.
- W4295881566 hasAuthorship W4295881566A5015613174 @default.
- W4295881566 hasAuthorship W4295881566A5039695487 @default.
- W4295881566 hasAuthorship W4295881566A5053931061 @default.
- W4295881566 hasAuthorship W4295881566A5064763469 @default.
- W4295881566 hasBestOaLocation W42958815661 @default.
- W4295881566 hasConcept C112705442 @default.
- W4295881566 hasConcept C126322002 @default.
- W4295881566 hasConcept C2776481607 @default.
- W4295881566 hasConcept C2776694085 @default.
- W4295881566 hasConcept C2777288759 @default.
- W4295881566 hasConcept C2777583451 @default.
- W4295881566 hasConcept C2778729363 @default.
- W4295881566 hasConcept C2779536868 @default.
- W4295881566 hasConcept C71924100 @default.
- W4295881566 hasConcept C90924648 @default.
- W4295881566 hasConcept C98274493 @default.
- W4295881566 hasConceptScore W4295881566C112705442 @default.
- W4295881566 hasConceptScore W4295881566C126322002 @default.
- W4295881566 hasConceptScore W4295881566C2776481607 @default.
- W4295881566 hasConceptScore W4295881566C2776694085 @default.
- W4295881566 hasConceptScore W4295881566C2777288759 @default.
- W4295881566 hasConceptScore W4295881566C2777583451 @default.
- W4295881566 hasConceptScore W4295881566C2778729363 @default.
- W4295881566 hasConceptScore W4295881566C2779536868 @default.
- W4295881566 hasConceptScore W4295881566C71924100 @default.
- W4295881566 hasConceptScore W4295881566C90924648 @default.
- W4295881566 hasConceptScore W4295881566C98274493 @default.
- W4295881566 hasIssue "12" @default.
- W4295881566 hasLocation W42958815661 @default.
- W4295881566 hasOpenAccess W4295881566 @default.
- W4295881566 hasPrimaryLocation W42958815661 @default.
- W4295881566 hasRelatedWork W1967535809 @default.
- W4295881566 hasRelatedWork W2342502240 @default.
- W4295881566 hasRelatedWork W2464182413 @default.
- W4295881566 hasRelatedWork W2625632249 @default.
- W4295881566 hasRelatedWork W2906094070 @default.
- W4295881566 hasRelatedWork W2906544898 @default.
- W4295881566 hasRelatedWork W2912912825 @default.
- W4295881566 hasRelatedWork W2992607765 @default.
- W4295881566 hasRelatedWork W3080817366 @default.
- W4295881566 hasRelatedWork W3180515128 @default.
- W4295881566 hasVolume "80" @default.
- W4295881566 isParatext "false" @default.
- W4295881566 isRetracted "false" @default.
- W4295881566 workType "article" @default.